Moleculin Biotech's total assets for Q2 2025 were $21.59M, an increase of 2.76% from the previous quarter. MBRX total liabilities were $28.76M for the fiscal quarter, a 37.13% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.